Xeris Reports Topline Results From Its Recently Completed Phase 2 Open Label, Study Of XP-8121 For Treatment Of Adults With Hypothyroidism
Portfolio Pulse from Benzinga Newsdesk
Xeris reported positive topline results from its Phase 2 study of XP-8121 for hypothyroidism treatment, showing higher treatment satisfaction and preference for SC administration. An FDA interaction for Phase 3 is expected by year-end.
May 30, 2024 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xeris reported positive Phase 2 results for XP-8121, showing higher treatment satisfaction and preference for SC administration. An FDA interaction for Phase 3 is expected by year-end.
The positive Phase 2 results and high patient satisfaction with XP-8121, along with the upcoming FDA interaction for Phase 3, are likely to boost investor confidence and positively impact Xeris' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100